Suzano Reports Operating Cash Generation of R$4.7 Billion in the First Quarter of 2023
28.4.2023 00:56:00 EEST | Business Wire | Press release
Suzano , the world’s largest hardwood pulp producer, announces its financial statements for the first quarter of 2023 (1Q23).
- Net revenues of R$11.3 billion, a 16% increase on 1Q22
- Adjusted EBITDA of R$6.2 billion, a 20% increase on 1Q22
- Operating cash generation of R$4.7 billion, a 21% increase on 1Q22
- Pulp sales totaled 2.5 million tons, a 3% increase on 1Q22
- Paper sales totaled 280 thousand tons, a 10% decrease on 1Q22
- Cash production cost (excluding downtimes) increased by 8% during the quarter to R$937 per ton
- Net income of R$5.2 billion
The start of the 2023 period has seen pulp prices significantly decline, reflecting the expectation of new market supply. Within this challenging context, Suzano was able to deliver solid results, demonstrating the company’s ability to navigate on a more acid market scenario.
The quarterly results contributed to a flat net debt balance, even during company’s largest investment cycle to date. Between January and March, Suzano invested R$3.7 billion, R$1.9 billion of which has been allocated to the construction of a pulp mill in the municipality of Ribas do Rio Pardo, Mato Grosso do Sul state. Between 2019 and 2022, the total capital expenditure in new projects, maintenance, modernization and others reached R$32.7 billion.
At the same time, Suzano’s net debt to adjusted EBITDA leverage in US dollars fell from 2.0x at the end of 2022 to 1.9x at the end of 1Q23. Net debt totaled US$10.9 billion at the end of March.
Walter Schalka, CEO of Suzano, said:
“Throughout 2022, Suzano took advantage of a strong cash generation as a result of a high pulp environment to advance its strategic agenda while also preparing for a price correction cycle such as the one that we have seen at the start of this year. Due to our financial discipline and structural competitiveness, we remain well-placed to continue ahead with our planned investments, which will be the largest in our history.”
Suzano has also launched its 2022 Sustainability Report and it´s Sustainability Center, a hub of resources dedicated exclusively to the company’s sustainability aspects.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230427006017/en/
Contact information
Hawthorn Advisors
Jamie Plotnek
suzano@hawthornadvisors.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Smartsheet Unveils vsActual: The AI-Native Platform that Connects Strategy to Execution at ENGAGE 20264.11.2026 19:00:00 EET | Press release
Smartsheet, the AI-powered enterprise work management platform, today unveiled a new AI-native strategic planning and execution product at ENGAGE 2026, its annual customer conference. vsActual is designed to solve the two biggest obstacles to enterprise execution: siloed work scattered across disconnected systems and teams, and the manual tracking and reporting that keeps individuals and executives from seeing problems until it’s too late. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104989965/en/ Today, Smartsheet unveiled a new AI-native strategic planning and execution product, vsActual. AI is helping individuals move faster than ever, but it's also making it harder to keep everyone moving in the same direction. In fact, a PMI research report found that leaders cited the disconnect between planning and execution as the biggest barrier to reinventing their businesses, and VentureBeat Intelligence found that 64% of res
SES Achieves Optical Communications Milestone for Future meoSphere Network4.11.2026 19:00:00 EET | Press release
SES, in collaboration with leading space technology partners, has successfully demonstrated a bi-directional optical communications link between ground and space through its meoSphere Pathfinder 1 mission, marking an important milestone in the development of the company's next-generation meoSphere network. The achievement validates a critical technology that will support future high-capacity, secure and flexible connectivity services. During the demonstration, SES successfully transmitted video messages from CEO Adel Al-Saleh over a bidirectional optical communications link between Cailabs' optical ground station in Rennes, France, and an SES payload flying on K2’s GRAVITAS mission on their Mega-class satellite platform. The mission utilized a Mynaric CONDOR optical terminal onboard. SES designed, developed, and operated the optical mission and developed automation software that enabled the demonstration. Thales Alenia Space supported system assembly, integration, testing and operation
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom